Fundz

Aureka Biotechnologies raises US$100 million in Series B funding led by Granite Asia and strategic investors. The funds will enhance their AI-driven drug discovery models and research.

PRIVATEAug 11, 2026

Amount Raised

$100 Million

Round Type

Series B

BiotechnologyTherapeutics

Investors

Highlight CapitalMPCiMp CiNRL CapitalGranite Asia

Description

Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, while a prominent strategic investor led a subsequent tranche. Participation also came from HighLight Capital and existing shareholders including MPCi and NRL Capital

Quick answer

Aureka Biotechnologies raised $100 Million in a Series B round, dated August 11, 2026. Investors: Highlight Capital, MPCi, Mp Ci, NRL Capital and Granite Asia.

How much did Aureka Biotechnologies raise?
Aureka Biotechnologies raised $100 Million in a Series B round on August 11, 2026.
Who invested in Aureka Biotechnologies?
Highlight Capital, MPCi, Mp Ci, NRL Capital and Granite Asia are named as investors in this round.
What does Aureka Biotechnologies do?
Aureka Biotechnologies is focused on developing generative antibody drugs through three core technology platforms: a generative intelligence platform, a yeast intracellular directed evolution platform, and a..
Where is Aureka Biotechnologies based and how big is it?
Fundz records about 42 employees.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Aureka Biotechnologies that raised within 45 days of this round, from Fundz verified event records.

  • Rejuvenation Technologies raised an undisclosed amount on September 24, 2026.
  • Kasvu Therapeutics raised $34M (Series A) on September 24, 2026.
  • United Immunity raised $14M (Debt Financing) on September 24, 2026.
  • Aqua Medical raised an undisclosed amount (Series B) on September 23, 2026.
  • ViferaXS raised $14M (Series A) on September 23, 2026.
  • Kinoxis Therapeutics raised $5M (Seed) on September 23, 2026.

Who to call at Aureka Biotechnologies, and when

A new round usually means Aureka Biotechnologies is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Aureka Biotechnologies raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Aureka Biotechnologies, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Aureka Biotechnologies. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Aureka Biotechnologies

About

Aureka Biotechnologies is focused on developing generative antibody drugs through three core technology platforms: a generative intelligence platform, a yeast intracellular directed evolution platform, and a microfluidic single-cell screening platform. The company aims to create a data-driven model that enhances the efficiency of antibody drug development, significantly increasing the number of breakthrough pipelines. Aureka's innovative approach incorporates autonomous agents to lead design hypotheses, redefining traditional drug development methodologies. This positions the company as a leader in addressing the shortcomings of conventional antibody drug design.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Aureka Biotechnologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Aureka Biotechnologies's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Aureka Biotechnologies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.